drinking with glp-1 Ozempic and Other Drugs for Alcoholism: Do They Work? What Alcohol Actually Does to

Description

[3] The bad news is they are still really expensivelike more than my car payment

The infarction zone rather than the noninfarcted remodeling zone overexpresses angiotensin II receptor type 1 and is the main source of ventricular atrial natriuretic peptide

Recently, very long-chain fatty acids glucosylceramides (C22 GlcCer) have been shown to be elevated in glp-1(-) mutants and are crucial for maintaining lysosomal function and promoting longevity 64 , further bolstering a role of sphingolipid metabolism in lifespan regulation

Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est